The Growing Interest in The Field of Non-Invasive Cancer Diagnostics

As the number of players involved in the development of liquid biopsy and other non-invasive cancer diagnostics continue to increase, recent years have witnessed several partnerships and collaborations being established between various stakeholders involved in this domain. The number of partnerships has increased significantly between 2016 and 2018, at a CAGR of 106%. It is important to highlight that the maximum number of partnerships (62) were signed in 2018. Majority of the deals (15) signed in 2018 were distribution and supply agreements. This is followed by 13 research and development agreements.

Distribution and supply agreements account for 22% of the total number of deals inked in the given period of time. This can be primarily attributed to the fact that over 160 products are now commercially available and test developers intend to improve the access of these tests across multiple regions. Companies involved in such agreements include (in alphabetical order, no selection criteria) Biodesix, Lucence Diagnostics, and OncoDNA.

The maximum number of partnerships (41%) have been signed for ctDNA-based tests. It is worth highlighting that liquid biopsies that determine ctDNA capture a significant portion (accounting for 31%) of the pipeline (presented in chapter 5 of this report). In fact, several clinical studies data suggest that the proportion of ctDNA in circulation can be corelated with tumor burden and overall survival. The companies focused on the development of ctDNA-based diagnostics include (in alphabetical order, no selection criteria) Admera Health, Inivata, and Sysmex Inostics.

Further, 17% of the deals were related to CTC-based diagnostics. Examples of recently signed research and development agreements for tests identifying CTCs include collaboration between Biocept and Agiomix (2019), EKF Molecular Diagnostics and ANGLE (2019), and Celsee and IncellDx (2018).

Furthermore, companies based in North America, particularly the US, were involved in majority of the intercontinental and intracontinental partnership activity. In addition, companies based in the EU and the US were involved in over 90 intracontinental deals. On the other hand, only a few intracontinental partnerships were recorded in Asia-Pacific; this is primarily because of the relatively lower number of developers based in Asian countries.

Sponsor Ads

• Ad Space Available - Rent it Now!

Report this Page

Created on Jun 24th 2020 09:08. Viewed 376 times.

Share on APSense

Comments